Whereas Cdk5 phosphorylates liprinα1 at Thr701, this phosphorylation decreases in neurons in response to neuronal activity. Blockade of liprinα1 phosphorylation enhances the structural and functional ...

While inhibitors of Cdk5 could offer potential therapeutic benefits and new ways to study basic brain function, previous first- and second-generation anti-Cdk5 compounds largely get blocked at the ...

To date, no Cdk5 inhibitor has been approved to treat any neuropsychiatric or degenerative diseases. Bibb and colleagues now report details of their anti-Cdk5, brain-permeable compound, 25-106.